X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4018) 4018
Publication (244) 244
Book Review (47) 47
Book Chapter (25) 25
Dissertation (4) 4
Conference Proceeding (2) 2
Book / eBook (1) 1
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2655) 2655
humans (2511) 2511
diabetes mellitus, type 2 - drug therapy (1830) 1830
type 2 diabetes (1504) 1504
male (1417) 1417
endocrinology & metabolism (1374) 1374
dipeptidyl-peptidase iv inhibitors - therapeutic use (1231) 1231
diabetes (1208) 1208
dipeptidyl peptidase-4 inhibitor (1182) 1182
hypoglycemic agents - therapeutic use (1162) 1162
female (1094) 1094
glucagon-like peptide-1 (1015) 1015
middle aged (897) 897
animals (896) 896
sitagliptin (884) 884
dipeptidyl peptidase-4 inhibitors (849) 849
pharmacology & pharmacy (776) 776
aged (734) 734
glucose (714) 714
metformin (676) 676
double-blind (674) 674
glycemic control (643) 643
treatment outcome (618) 618
dipeptidyl-peptidase iv inhibitors - pharmacology (613) 613
diabetes mellitus, type 2 - blood (596) 596
diabetes mellitus (578) 578
insulin (572) 572
hypoglycemic agents (557) 557
hypoglycemic agents - adverse effects (527) 527
dipeptidyl-peptidase iv inhibitors - adverse effects (526) 526
adult (508) 508
type 2 diabetes mellitus (487) 487
safety (475) 475
type-2 diabetes-mellitus (470) 470
care and treatment (469) 469
blood glucose - metabolism (468) 468
adamantane - analogs & derivatives (457) 457
vildagliptin (450) 450
drug therapy, combination (447) 447
efficacy (438) 438
analysis (431) 431
drug therapy (428) 428
blood glucose - drug effects (426) 426
dipeptidyl peptidase-4 (415) 415
internal medicine (414) 414
risk factors (412) 412
sitagliptin phosphate (412) 412
dipeptidyl peptidase 4 - metabolism (408) 408
hypoglycemic agents - administration & dosage (408) 408
research (396) 396
hypoglycemic agents - pharmacology (388) 388
beta-cell function (378) 378
mice (376) 376
dipeptidyl-peptidase iv inhibitors - administration & dosage (366) 366
diabetes therapy (362) 362
medicine, general & internal (359) 359
dpp-4 inhibitor (354) 354
glucagon (347) 347
dextrose (339) 339
medicine & public health (338) 338
metformin - therapeutic use (335) 335
linagliptin (333) 333
glycated hemoglobin a - metabolism (332) 332
diabetes mellitus, type 2 - complications (329) 329
improves glycemic control (321) 321
mellitus (320) 320
peptidase (318) 318
hyperglycemia (309) 309
glp-1 (307) 307
insulin resistance (306) 306
rats (304) 304
adamantane - therapeutic use (279) 279
double-blind method (279) 279
hypoglycemia (279) 279
clinical trials (277) 277
diabetes mellitus, type 2 - metabolism (276) 276
therapy (272) 272
peptides (271) 271
dosage and administration (265) 265
health aspects (261) 261
cardiac & cardiovascular systems (255) 255
triazoles - therapeutic use (254) 254
dpp-4 inhibitors (252) 252
pyrazines - therapeutic use (251) 251
abridged index medicus (249) 249
medicine, research & experimental (249) 249
incretin (244) 244
saxagliptin (235) 235
obesity (227) 227
studies (224) 224
review (223) 223
pharmacokinetics (222) 222
risk (220) 220
inflammation (219) 219
oxidative stress (216) 216
diabetes mellitus, type 2 - physiopathology (206) 206
glycosylated hemoglobin (205) 205
monotherapy (202) 202
drug-naive patients (201) 201
incretins - therapeutic use (200) 200
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3886) 3886
German (27) 27
French (25) 25
Japanese (25) 25
Korean (20) 20
Russian (14) 14
Spanish (14) 14
Hungarian (8) 8
Chinese (4) 4
Italian (4) 4
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Polish (1) 1
Slovenian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
The Lancet, ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and... 
MEDICINE, GENERAL & INTERNAL | IN-VITRO | METFORMIN-TREATED PATIENTS | HEALTHY-SUBJECTS | 2ND-PHASE INSULIN-SECRETION | IMPROVES GLYCEMIC CONTROL | BETA-CELL APOPTOSIS | IV INHIBITOR | 7-36 AMIDE | IMPROVED GLUCOSE-TOLERANCE | EXENATIDE SYNTHETIC EXENDIN-4 | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Diagnosis | Glucagon | Analysis | Dosage and administration | Research | Protease inhibitors | Drug therapy | Proteins | Diabetes | Kinases | Insulin | Rodents
Journal Article